Penumbra (PEN) EBT Growth (3y) (2017 - 2026)
Penumbra (PEN) EBT Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -2.47% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 7.77% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 5.75% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 37.81% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 4.82% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 61.06% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 32.11% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -2.57% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Penumbra | 12.48 Bn | 11.87 Bn | 253.41 Mn | 68.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68.90% |
| Dec 31, 2025 | 107.44% |
| Sep 30, 2025 | 158.34% |
| Jun 30, 2025 | 244.33% |
| Mar 31, 2025 | 119.62% |
| Dec 31, 2024 | 45.54% |
| Sep 30, 2024 | 72.26% |
| Jun 30, 2024 | -112.77% |
| Mar 31, 2024 | 5.47% |
| Dec 31, 2023 | 324.83% |
| Sep 30, 2023 | 38.80% |
| Jun 30, 2023 | 46.55% |
| Mar 31, 2023 | 138.68% |
| Dec 31, 2022 | -15.34% |
| Sep 30, 2022 | -38.37% |
| Jun 30, 2022 | -27.78% |
| Mar 31, 2022 | -34.42% |
| Dec 31, 2021 | -96.37% |
| Sep 30, 2021 | 33.72% |
| Jun 30, 2021 | 1.83% |